Compare GSK plc (GSK) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Snap On Incorporated — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Snap On Incorporated trades at $360.37 (market cap $18.56B). The key difference: GSK plc is far larger — about 5× Snap On Incorporated's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Snap On Incorporated for 37 Days on average.
| GSK | SNA | |
|---|---|---|
Market Cap | $91.88B | $18.56B |
Volume | 7,730,529 | 401,326 |
Sector | Health | Industrials |
52-Week High | $61.18 | $419.31 |
52-Week Low | $43.24 | $327.33 |
Typical Hold Time | 93 Days | 37 Days |
Enterprise Value | $111.88B | $18.20B |
Dividend Yield | 3.9% | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Snap-On Incorporated (SNA) trades at $358.88, down 0.28% on the day, with a bearish technical signal from moving averages and oscillators. The company reported solid fundamentals with a 19.6% net income margin and a 17.58% ROE for 2025. Recent earnings show a mix of beats and a miss, with Q3 2026 results pending. Analyst consensus is bullish with a $449 price target, but technical indicators suggest near-term caution amid institutional position adjustments.
The outlook for SNA is supported by strong profitability and analyst optimism, but faces headwinds from technical bearishness and valuation risks. Investment opportunity lies in execution of RCI initiatives and diagnostic segment growth, while risks include integration costs from acquisitions and softer OEM demand. The stock's premium valuation requires sustained earnings growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
